WO2012068531A3 - Novel compositions and uses of anti-hypertension agents for cancer therapy - Google Patents
Novel compositions and uses of anti-hypertension agents for cancer therapy Download PDFInfo
- Publication number
- WO2012068531A3 WO2012068531A3 PCT/US2011/061510 US2011061510W WO2012068531A3 WO 2012068531 A3 WO2012068531 A3 WO 2012068531A3 US 2011061510 W US2011061510 W US 2011061510W WO 2012068531 A3 WO2012068531 A3 WO 2012068531A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer therapy
- novel compositions
- cancer
- compositions
- hypertension agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11841427.5A EP2640359A4 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
AU2011329638A AU2011329638C1 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
CA2817250A CA2817250A1 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
RU2013127625/15A RU2013127625A (en) | 2010-11-18 | 2011-11-18 | NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY |
CN201180065389.2A CN103561726A (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
JP2013540082A JP2014505666A (en) | 2010-11-18 | 2011-11-18 | Antihypertensive composition and use for cancer treatment |
US13/834,094 US20130287688A1 (en) | 2010-11-18 | 2013-03-15 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41519210P | 2010-11-18 | 2010-11-18 | |
US61/415,192 | 2010-11-18 | ||
US201161438240P | 2011-01-31 | 2011-01-31 | |
US61/438,240 | 2011-01-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/834,094 Continuation-In-Part US20130287688A1 (en) | 2010-11-18 | 2013-03-15 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012068531A2 WO2012068531A2 (en) | 2012-05-24 |
WO2012068531A3 true WO2012068531A3 (en) | 2013-11-28 |
Family
ID=46084685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/061510 WO2012068531A2 (en) | 2010-11-18 | 2011-11-18 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2640359A4 (en) |
JP (2) | JP2014505666A (en) |
CN (1) | CN103561726A (en) |
AU (1) | AU2011329638C1 (en) |
CA (1) | CA2817250A1 (en) |
RU (2) | RU2013127625A (en) |
WO (1) | WO2012068531A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1583562B1 (en) | 2003-01-06 | 2011-06-15 | Angiochem Inc. | Angiopep-1, related compounds, and uses thereof |
DK2433653T3 (en) | 2005-07-15 | 2019-08-19 | Angiochem Inc | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
TR201905480T4 (en) | 2008-04-18 | 2019-05-21 | Angiochem Inc | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and their respective preparation and use methods. |
CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
EP2346896A4 (en) | 2008-10-15 | 2014-06-25 | Angiochem Inc | Etoposide and doxorubicin conjugates for drug delivery |
BRPI0922689A2 (en) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | neurotensin conjugates or neurotensin analogs and uses thereof |
CN102300987A (en) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | Membrane Type-1 Matrix Metalloprotein Inhibitors And Uses Thereof |
RU2011146654A (en) | 2009-04-20 | 2013-05-27 | Ангиокем Инк. | METHODS FOR TREATING OVARIAN CANCER USING CONJUGATED PRODUCT |
IN2012DN00248A (en) | 2009-07-02 | 2015-05-01 | Angiochem Inc | |
JP6378170B2 (en) | 2012-04-12 | 2018-08-22 | イェール ユニバーシティーYale University | Vehicle for controlled delivery of different pharmaceuticals |
EP2866791A4 (en) * | 2012-05-07 | 2016-04-20 | Gen Hospital Corp | Novel compositions and uses of anti-hypertension agents for cancer therapy |
US9486503B2 (en) | 2012-10-04 | 2016-11-08 | Shionogi & Co., Ltd. | Medicinal agent for suppressing malignant tumor metastasis |
CN111329989A (en) * | 2012-11-02 | 2020-06-26 | 药品循环有限责任公司 | TEC family kinase inhibitor adjuvant therapy |
WO2014129914A1 (en) * | 2013-02-22 | 2014-08-28 | Auckland Uniservices Limited | Methods of treatment |
US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
WO2014134621A2 (en) * | 2013-03-01 | 2014-09-04 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
JP6702722B2 (en) * | 2013-04-10 | 2020-06-03 | 公立大学法人奈良県立医科大学 | Preventive and/or therapeutic agent for hepatocellular carcinoma |
CA2987519A1 (en) * | 2013-11-01 | 2015-05-07 | Yale University | Delivery vehicles |
CA2922575C (en) * | 2013-11-01 | 2022-10-11 | Newsouth Innovations Pty Limited | Pharmaceutical combinations for the treatment of cancer |
US20180117006A1 (en) * | 2015-04-25 | 2018-05-03 | The General Hospital Corporation | Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer |
CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
CN105326812A (en) * | 2015-10-28 | 2016-02-17 | 南昌大学 | Sorafenib solid lipid nanoparticles and preparation method thereof |
US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
TWI771315B (en) | 2016-08-26 | 2022-07-21 | 奧野哲治 | Nanominiaturized agent and utilization thereof |
TW201815418A (en) * | 2016-09-27 | 2018-05-01 | Vertex Pharma | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
CN108358995B (en) * | 2017-01-25 | 2021-07-06 | 四川大学 | CP-iRGD polypeptide, iDPP nanoparticle, drug-loaded compound and preparation method and application thereof |
RU2724398C1 (en) * | 2019-09-03 | 2020-06-23 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for determining aggressiveness of lung cancer |
BR112022010163A2 (en) * | 2019-12-13 | 2022-08-09 | Massachusetts Inst Technology | GROWTH OF CATALYZED POLYMER IN TISSUE AS EPITHELIAL COATINGS FOR THERAPY |
EP3842099A1 (en) * | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Use of losartan for the treatment of fibrotic diseases, in particular epidermolysis bullosa |
CN114917345A (en) * | 2021-04-07 | 2022-08-19 | 北京蛋白质组研究中心 | Application of compound targeting SOAT1 protein in preparation of medicine for preventing and/or treating liver cancer |
CN115317627B (en) * | 2022-08-26 | 2023-10-24 | 江西中医药大学 | Application of ABT-510 peptide in preparation of tumor imaging agent |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010019715A1 (en) * | 1997-09-18 | 2001-09-06 | Idec Pharmaceuticals Corporation | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US20070129331A1 (en) * | 2004-04-20 | 2007-06-07 | Rnd Pharmaceuticals, Inc. | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives |
US20080063724A1 (en) * | 2005-02-18 | 2008-03-13 | Desai Neil P | Methods and compostions for treating proliferative diseases |
US20090012052A1 (en) * | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
US20090220588A1 (en) * | 2008-02-21 | 2009-09-03 | Massachusetts Institute Of Technology | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US6719977B1 (en) | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
DE10144980B4 (en) | 2001-09-12 | 2004-06-03 | Webasto Vehicle Systems International Gmbh | Guide device for a lid of a vehicle roof to be opened |
AU2005269800B8 (en) | 2004-07-19 | 2011-12-01 | Celator Pharmaceuticals, Inc. | Particulate constructs for release of active agents |
TWI386225B (en) | 2004-12-23 | 2013-02-21 | Alcon Inc | Rnai inhibition of ctgf for treatment of ocular disorders |
WO2006077901A1 (en) | 2005-01-20 | 2006-07-27 | Shionogi & Co., Ltd. | Ctgf expression inhibitor |
BRPI0607639B1 (en) | 2005-02-08 | 2022-04-05 | Genzyme Corporation | Human antibody molecules or antigen-binding fragments thereof that bind and neutralize tgf-beta1, 2 and 3, their use and pharmaceutical composition |
WO2007109097A2 (en) | 2006-03-16 | 2007-09-27 | Alnylam Pharmaceuticals, Inc. | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF |
EP2285350B1 (en) | 2008-06-16 | 2017-11-15 | Pfizer Inc | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (en) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | Long-circulating nanoparticles for sustained release of therapeutic agents |
DE202009018883U1 (en) | 2009-04-24 | 2014-03-12 | BSH Bosch und Siemens Hausgeräte GmbH | Program selector for a domestic appliance, in particular for a washing machine |
-
2011
- 2011-11-18 RU RU2013127625/15A patent/RU2013127625A/en not_active Application Discontinuation
- 2011-11-18 CA CA2817250A patent/CA2817250A1/en not_active Abandoned
- 2011-11-18 WO PCT/US2011/061510 patent/WO2012068531A2/en active Application Filing
- 2011-11-18 CN CN201180065389.2A patent/CN103561726A/en active Pending
- 2011-11-18 AU AU2011329638A patent/AU2011329638C1/en active Active
- 2011-11-18 RU RU2018102375A patent/RU2018102375A/en not_active Application Discontinuation
- 2011-11-18 EP EP11841427.5A patent/EP2640359A4/en not_active Withdrawn
- 2011-11-18 JP JP2013540082A patent/JP2014505666A/en not_active Withdrawn
-
2017
- 2017-02-06 JP JP2017019388A patent/JP2017101056A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010019715A1 (en) * | 1997-09-18 | 2001-09-06 | Idec Pharmaceuticals Corporation | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US20070129331A1 (en) * | 2004-04-20 | 2007-06-07 | Rnd Pharmaceuticals, Inc. | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives |
US20080063724A1 (en) * | 2005-02-18 | 2008-03-13 | Desai Neil P | Methods and compostions for treating proliferative diseases |
US20090012052A1 (en) * | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
US20090220588A1 (en) * | 2008-02-21 | 2009-09-03 | Massachusetts Institute Of Technology | Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity |
US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
Non-Patent Citations (1)
Title |
---|
See also references of EP2640359A4 * |
Also Published As
Publication number | Publication date |
---|---|
CN103561726A (en) | 2014-02-05 |
RU2018102375A (en) | 2019-02-21 |
WO2012068531A2 (en) | 2012-05-24 |
CA2817250A1 (en) | 2012-05-24 |
RU2013127625A (en) | 2014-12-27 |
EP2640359A2 (en) | 2013-09-25 |
JP2014505666A (en) | 2014-03-06 |
AU2011329638B2 (en) | 2016-10-13 |
JP2017101056A (en) | 2017-06-08 |
AU2011329638A1 (en) | 2013-05-30 |
EP2640359A4 (en) | 2015-11-04 |
AU2011329638C1 (en) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012068531A3 (en) | Novel compositions and uses of anti-hypertension agents for cancer therapy | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
MX342951B (en) | Therapeutically active compositions and their method of use. | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
WO2012009406A3 (en) | Gold particles and methods of making and using the same in cancer treatment | |
EP2294184A4 (en) | Treatment of eye diseases and excessive neovascularization using a combined therapy | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
MX2019000225A (en) | Compositions and methods for treatment of autoimmune and other disease. | |
MX358491B (en) | A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate. | |
MX2012002977A (en) | Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs. | |
MX2014002171A (en) | Combination treatments for hepatitis c. | |
WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
MD20140123A2 (en) | Optimised subcutaneous therapeutic agents | |
WO2013134407A3 (en) | Procaspase 3 activation by combination therapy | |
WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
GB201213267D0 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
WO2012040331A3 (en) | Multistage nanoparticles | |
IN2015DN01328A (en) | ||
WO2010033884A3 (en) | Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant | |
MX2015002573A (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell. | |
WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
WO2009132234A3 (en) | Medical devices, polymers, compositions, and methods for delivering a haloacetate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11841427 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2817250 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013540082 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011329638 Country of ref document: AU Date of ref document: 20111118 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011841427 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013127625 Country of ref document: RU Kind code of ref document: A |